# A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

> **NCT00436826** · PHASE2 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 172 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Placebo
- **DRUG:** Interferon-beta (IFN-beta)

## Key facts

- **NCT ID:** NCT00436826
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-30
- **Primary completion:** 2011-09-30
- **Final completion:** 2012-03-31
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436826, "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00436826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*